Risk of vertical transmission | Prophylactic regimen | ||
Formula-fed newborns at low risk | |||
|
| ||
|
| ||
Breast-fed newborns at low risk | |||
|
| ||
Formula-fed newborns at high risk | |||
|
| ||
Drug | Gestational age at birth | Dosing§ | |
Zidovudine (ZDV)¥ | ≥35 weeks |
| |
Weight band (kg) | Volume (mL) ZDV 10 mg/mL oral syrup twice daily | ||
2 to <3 kg | 1 mL | ||
3 to <4 kg | 1.5 mL | ||
4 to <5 kg | 2 mL | ||
≥30 to <35 weeks |
| ||
<30 weeks |
| ||
Abacavir (ABC)‡ | ≥37 weeks |
| |
Lamivudine (3TC) | ≥32 weeks |
| |
Nevirapine (NVP)† | ≥37 weeks |
| |
≥34 to <37 weeks |
| ||
≥32 to <34 weeks** |
| ||
Raltegravir (RAL)ΔΔ,◊◊ | ≥37 weeks and weighing ≥2 kg | Body weight (kg) | Volume (dose) of RAL 10 mg/mL suspension |
Birth to 1 week: Once-daily dosing, approximately 1.5 mg/kg/dose | |||
2 to <3 kg | 0.4 mL (4 mg) once daily | ||
3 to <4 kg | 0.5 mL (5 mg) once daily | ||
4 to <5 kg | 0.7 mL (7 mg) once daily | ||
1 to 4 weeks: Twice-daily dosing, approximately 3 mg/kg/dose | |||
2 to <3 kg | 0.8 mL (8 mg) twice daily | ||
3 to <4 kg | 1 mL (10 mg) twice daily | ||
4 to <5 kg | 1.5 mL (15 mg) twice daily | ||
4 to 6 weeks: Twice-daily dosing, approximately 6 mg/kg/dose | |||
3 to <4 kg | 2.5 mL (25 mg) twice daily | ||
4 to <6 kg | 3 mL (30 mg) twice daily | ||
6 to <8 kg | 4 mL (40 mg) twice daily |
ART: antiretroviral therapy; NAAT: nucleic acid amplification test; IV: intravenous; BSA: body surface area; FDA: US Food and Drug Administration; UGT1A1: uridine diphosphate glucotransferase.
* Primary HIV infection refers to the first 6 months of infection.
¶ This statement only applies to individuals who are diagnosed with HIV while breastfeeding.
Δ The optimal duration of presumptive HIV therapy in newborns at high risk of vertical HIV transmission is unknown. We favor a 3-drug regimen for 6 weeks. An alternative approach to using a 3-drug regimen for the full 6-week duration, particularly if there are side effects or complications, is to discontinue the 3TC and NVP or RAL components after 2 weeks if the HIV NAAT at birth was negative and continue ZDV alone for the full 6 weeks. In highly select cases, a two-drug regimen might be appropriate. Consultation with an expert in pediatric HIV for regimen selection is recommended.
◊ Raltegravir (instead of nevirapine) should be used in infants at risk of HIV-2 infection.
§ These doses are only for the prophylaxis regimens in infants without confirmed HIV infection. Continuation of ART with potential regimen and/or dose adjustments is warranted for infants who are diagnosed with HIV infection.
¥ For newborns who are unable to tolerate oral agents, the IV dose is 75% of the oral dose while maintaining the same dosing interval.
‡ ABC is not approved by FDA for use in infants aged <3 months. Dosing recommendations have been modeled using pharmacokinetic simulation. Prior to using abacavir, negative testing for HLA-B5701 allele should be confirmed.
† Investigational NVP treatment dose recommended by the United States Department of Health and Human Services; the FDA has not approved a dose of NVP for infants <1 month of age.
** These doses may underestimate potential toxicity in infants in this age group as the doses are based on modeling and lower doses were used to develop the model than what is now recommended.
¶¶ Only make this dose increase for infants with confirmed HIV infection or in breastfed infants older than 6 weeks whose mother is found to have new onset viremia and 6-week presumptive therapy is initiated pending infant HIV status.
ΔΔ If the mother has taken RAL 2 to 24 hours prior to delivery, the neonate's first dose of RAL should be delayed until 24 to 48 hours after birth; ZDV and 3TC, however, should be started as soon as possible after birth. RAL dosing is increased at 1 and 4 weeks of age because metabolism by UGT1A1 is low at birth and increases rapidly during the next 4 to 6 weeks of life. If the two dose changes in the first month of life seem challenging for a family, an alternative is to increase to the 3 mg/kg twice daily dose upon discharge on day 4 or 5 of life.
◊◊ No dosing information for RAL is available for preterm or infants weighing <2 kg at birth.آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟